Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rahul Banerjee MD, FACP

Rahul Banerjee MD, FACP

Assistant Professor, Clinical Research Division, Fred Hutchinson Cancer Center, and Division of Hematology & Oncology, University of Washington, Seattle, Washington

Dr. Rahul Banerjee, MD, FACP, (Twitter/X: @RahulBanerjeeMD) is an Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington in Seattle, Washington. His clinical interests are in multiple myeloma and CAR-T therapy. He is a member of the International Myeloma Working Group and has published over 70 peer-reviewed publications with an emphasis on improving the experiences of patients as they undergo treatment for multiple myeloma.

Disclosures

Dr. Banerjee reports the following:
  • Consulting: Adaptive Biotech, BMS, Caribou Biosciences, Genentech/Roche, GSK, Karyopharm, Legend Biotech, JNJ, Pfizer, Sanofi Pasteur, SparkCures
  • Research funding: Abbvie, BMS, JNJ, Novartis, Pack Health, Prothena, Sanofi

Recent Contributions to PracticeUpdate:

  1. Daratumumab With Lenalidomide as Maintenance Therapy After Transplant for Newly Diagnosed Multiple Myeloma
  2. Impact of Dexamethasone Dose Reduction During Induction Therapy in Patients With Newly Diagnosed Multiple Myeloma

Most Read This Week

Recently Updated